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introduction: Postoperative nausea and vomiting (PONV) is among the most common 
distressing complications of surgery under anesthesia. Previous studies have demon-
strated that patients who undergo craniotomy have incidences of nausea and vomiting 
as high as 50–70%. The main purpose of this pilot study is to assess the incidence of 
PONV by using two different prophylactic regimens in subjects undergoing a craniotomy. 
Thus, we designed this study to assess the efficacy and safety of triple therapy with the 
combination of dexamethasone, promethazine, and aprepitant versus ondansetron to 
reduce the incidence of PONV in patients undergoing craniotomy.
Materials and methods: This is a prospective, single center, two-armed, randomized, 
double-dummy, double-blind, pilot study. Subjects were randomly assigned to one 
of the two treatment groups. Subjects received 40 mg of aprepitant pill (or matching 
placebo pill) 30–60  min before induction of anesthesia and 4  mg of ondansetron IV 
(or 2 ml of placebo saline solution) at induction of anesthesia. In addition, all subjects 
received 25 mg of promethazine IV and 10 mg of dexamethasone IV at induction of 
anesthesia. Assessments of PONV commenced for the first 24 h after surgery and were 
subsequently assessed for up to 5 days.
results: The overall incidence of PONV during the first 24 h after surgery was 31.0% 
(n = 15) in the aprepitant group and 36.2% (n = 17) for the ondansetron group. The 
median times to first emetic and significant nausea episodes were 7.6 (2.9, 48.7) and 
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14.3 (4.4, 30.7) hours, respectively, for the aprepitant group and 6.0 (2.2, 29.5) and 
9.6 (0.7, 35.2) hours, respectively, for the ondansetron group. There were no statistically 
significant differences between these groups. No adverse events directly related to study 
medications were found.
Conclusion: This pilot study showed similar effectiveness when comparing the two 
PONV prophylaxis regimens. Our data showed that both treatments could be effective 
regimens to prevent PONV in patients undergoing craniotomy under general anesthesia. 
Future trials testing new PONV prophylaxis regimens in this surgical population should be 
performed to gain a better understanding of how to best provide prophylactic treatment.
Keywords: POnV, aprepitant, ondansetron, triple therapy, nausea, vomiting, craniotomy
inTrODUCTiOn
Nausea and vomiting are known to be among the most common 
distressing postsurgical complications. Both of these conditions 
are associated with prolonged post-anesthesia care, delayed 
patient recovery and discharge, and increased overall cost of 
surgical intervention (1–7).
As stated in the guidelines from the Society for Ambulatory 
Anesthesia (SAMBA), postoperative nausea and vomiting 
(PONV) has been defined as the occurrence of nausea and vomit-
ing during the first 24 h following a surgical procedure (1, 7).
Postoperative nausea and vomiting treatment and prevention 
may prove imperative to the postsurgical outcomes of patients 
undergoing craniotomies. For instance, retching and vomiting 
increases intracranial and intravascular pressure, leading to 
homeostatic changes and a decrease in cerebral perfusion (7). 
These factors are important to consider in neurosurgical settings 
as they can also increase the risk for brain swelling and surgical 
debridement following craniotomy (7). Furthermore, sedated 
patients are at higher risk of aspiration from vomiting due to 
the impairment of their airway reflexes; therefore, the use of 
antiemetic medications with few sedative properties are recom-
mended as the preferred course of treatment (1, 8, 9).
Currently, multiple antiemetic medications are available for 
PONV prophylaxis. In various studies, regimens using single, 
double, and triple antiemetic agents have been proposed for 
PONV prophylaxis in patients undergoing craniotomies (1, 4, 10). 
However, an amalgam of regimens is the preferred prophylactic 
therapy, due to the additive antiemetic effects in various receptors 
of the emetogenic pathway (1, 11).
Alongside antiemetic medications, non-pharmacological 
techniques can be used as an alternative in preventing PONV. 
A commonly cited example is pericardium 6 acupoint stimula-
tion, which reduces regurgitation and regulates gastric peristaltic 
movements (11). Despite mention of these strategies in the litera-
ture, these treatments have not yet been proven to be effective in 
preventing PONV (11).
One of the medications most commonly used for PONV 
prophylaxis is dexamethasone, an intravenous (IV) corticoster-
oid with anti-inflammatory properties, but with an unknown 
antiemetic mechanism of action (1, 8, 11). Data show that the 
use of dexamethasone enhances the post-discharge quality of 
recovery, in addition to reducing nausea, pain, and fatigue after 
surgery (8, 10, 12).
Promethazine is a phenothiazine with histamine (H1) antago-
nist activity. This time-tested antiemetic exults predominantly 
anti-dopaminergic effects as well as moderate anti-histaminic 
and anticholinergic properties. But, used at lower parental doses, 
promethazine has been reported to instigate highly sedative 
effects (3, 5, 13). Other risks are also attributed to promethazine. 
IV administration of promethazine may cause serious adverse 
reactions, including, but not limited to, contact dermatitis, 
inflammation, and venous thrombosis at the injection site (14). 
The drug also lowers the seizure threshold in patients with neu-
rological deficits, characteristic of our patient population (15).
Ondansetron is a serotonin (5HT3) receptor antagonist and 
the most commonly studied drug for the prophylaxis of PONV in 
craniotomy procedures. It is typically considered the “gold stand-
ard” of PONV prophylaxis medications, due to its antiemetic 
properties and lack of sedative effects, and, as such, is widely used 
(1). These antiemetic and non-sedative qualities are particularly 
beneficial for neurological assessments following craniotomies, 
as patients remain more lucid.
Aprepitant is a selective antagonist with high affinity for the 
human neurokinin (NK1) receptor, which reduces the emetic 
effect of substance P and leads to increased oral bioavailability 
(2, 9, 10, 16, 17). The NK1 receptors are located within areas of 
the gut associated with the emetic reflex (17). As an antagonist, 
this drug plays an important role in decreasing substance P, which 
may have antiemetic effects both in the central and peripheral 
nervous systems (17).
Therefore, in this prospective, two-armed, randomized, 
double-blind, double-dummy trial, we hypothesized that using 
a triple therapy of aprepitant, promethazine, and dexamethasone 
versus a triple therapy of ondansetron, promethazine, and 
dexamethasone will effectively reduce the incidence of PONV in 
patients undergoing craniotomy.
MaTErialS anD METHODS
Study Design and Patient Population
This study was designed as a randomized, double-blinded, 
doubled-dummy, single center, prospective pilot trial. After 
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obtaining institutional review board (Office of Responsible 
Research Practices) approval for the research protocol, a total of 
95 subjects provided their written informed consent before any 
study-related procedures began and completed the study at The 
Ohio State University Wexner Medical Center between January 
2009 and April 2012. The clinical trial registry number of this 
study is NCT01474915.
Study inclusion criteria consisted of neurosurgical patients 
whose ages ranged from 18 to 85 years, with an American Society 
of Anesthesiologist (ASA) physical status of I, II, or III, scheduled 
to undergo elective craniotomy (opening of the cranium and dura 
mater) requiring at least 1 h of general anesthesia. These patients 
also had moderate-to-severe risk for PONV as assessed by having 
two or more risk factors on the simplified Apfel score. Exclusion 
criteria consisted of prisoners or mentally ill status, past medical 
history of alcohol or drug abuse, history of allergy reaction or 
intolerance to any study medications, pregnant or breastfeeding 
subjects, history of nausea and/or vomiting within 24 h of their 
procedure, history of treatment with antiemetic medication for 
nausea or vomiting within 24 h of their procedure, and history 
of chemotherapy treatment within 4 weeks prior to surgery. Only 
patients having craniotomy procedures and requiring admission 
were included. Patients who had received any medication with 
antiemetic properties prior to surgery were excluded from par-
ticipating in the study.
The standardized anesthesia regimen also consisted of pre-
medication of midazolam 1–2 mg IV directly before transferring 
the patient to the operating room. Anesthesia was induced with 
propofol 1–2 mg/kg IV and fentanyl 0.75–1.5 μg/kg IV. Tracheal 
intubation was performed after the administration of rocuro-
nium 0.6–1.2  mg/kg IV. General anesthesia was maintained 
with volatile anesthetics (sevoflurane, desflurane, or isoflurane), 
and its titration concentration was guided on clinical judgment. 
Analgesia during anesthesia maintenance was provided with 
fentanyl boluses of 0.5–2.0 μg/kg IV. At the end of the procedure, 
neostigmine and glycopyrrolate were used to reverse residual 
neuromuscular block.
The method used for randomization was simple randomiza-
tion using a random list generator. Consistent with a double-
blind, double-dummy design, subjects were randomly assigned 
to one of the two treatment groups, Aprepitant or Ondansetron. 
Subjects received 40 mg of aprepitant pill (or matching placebo 
pill) 30–60  min before induction of anesthesia and 4  mg of 
ondansetron IV (or 2  ml of placebo saline solution) at induc-
tion of anesthesia. In addition, all subjects received 25  mg of 
promethazine IV and 10 mg of dexamethasone IV at induction 
of anesthesia. The health-care providers and researchers were 
blinded throughout the study, the only unblinded personnel 
was the pharmacist who prepared the study drug based on the 
randomization list.
Prior to surgery, vital signs and study safety procedures, 
including electrocardiogram (ECG), and urine or serum preg-
nancy tests were performed. Study medications were prepared 
by research pharmacists and administered during induction time 
(except aprepitant) by anesthesia care providers not involved in 
data collection. PONV assessments commenced after emergence 
from anesthesia and extubation time, and subjects were then 
transferred to the post-anesthesia care unit (PACU) or surgical 
intense care unit (SICU) when necessary.
Outcome Measurement
This study explored the effects of triple therapy to prevent PONV 
as a primary endpoint, which is defined as nausea and/or vomit-
ing during the first 24 h after a surgical procedure. Nausea was 
defined as any instance of feeling the urge to vomit and vomiting 
was defined as the ejection of gastric content through the mouth. 
Nausea was assessed by asking subjects to rate their nausea on a 
0–10 point scale, with 0 being no nausea at all and 10 being severe 
nausea. Vomiting was assessed by asking subjects to rate their 
vomiting on a 0–3 point scale, with 0 being no vomiting, 1 being 
mild vomiting (1–2 episode in 12  h, small amount of emesis), 
2 being moderate vomiting (3–5 episodes in 12 h, breakthrough 
vomiting), and 3 being severe vomiting (6–7 episodes in 12  h, 
intractable, incessant, projectile). After surgery, patients who 
experienced nausea and/or vomiting received ondansetron 
4  mg IV as the initial rescue medication for PONV. Choice of 
subsequent rescue antiemetic was left to the anesthesiologist’s 
discretion. First episode of nausea, vomiting, and rescue medica-
tion was recorded.
Anesthesia and surgical procedure start and end time, admis-
sion and discharge time from the PACU/SICU, and general care 
floor were recorded. As a secondary outcome, the influences 
of these regimens were assessed from 24  h after surgery up to 
5 days via direct subject interview and/or medical records review. 
Intraoperative medication and opioid daily consumption from 
PACU arrival time through a 5-day follow-up were collected. 
Subjects who were discharged before the end of a 5-day time 
period were contacted by telephone every 24 h to assess nausea 
and/or vomiting, rescue medication, opioid consumption, and 
adverse events and serious adverse events. Following the first 24 h 
after administration of the prophylactic triple therapy, an ECG 
was performed as part of safety assessments.
Statistical analysis
A previous study published in 2005 by Gan et al. compared the 
use of pre-operative dose of aprepitant 40 mg orally to ondanse-
tron 4 mg IV for prevention of PONV; the investigators reported 
that only 15% of the patients experienced vomiting in aprepitant 
group compared with 33% vomiting incidence in ondansetron 
group (18). In a two-sided test to compare the two proportions at 
0.05 significance level, n = 88 subjects per group were assigned in 
order to achieve 80% power.
However, after accruing more than 50% of the study partici-
pants, the overall PONV incidence was greater than anticipated; 
thus, the investigators decided to run an unplanned data analysis. 
The results of this unanticipated analysis showed only a 5.2% 
absolute difference in PONV (ondansetron group 36.2% versus 
aprepitant group 31%) between both groups, indicating that 
our estimation of sample size was not realistic. To detect such 
a small difference in proportion, an overall simple size of 2590 
patients (1295 per group) was required. Due to lack of statistical 
significance differences, we decided to stop the enrollment, and 
the available data are the subject of this publication. Descriptive 
FiGUrE 1 | Patient screening flowchart.
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statistics are reported as mean  ±  SD, median (range), total 
number, and percentage. The data were analyzed using Statistical 
Analysis Software, version 9.3 (SAS Institute Inc., Cary, NC, 
USA). Significance was accepted if P ≤ 0.05.
rESUlTS
A total of 121 subjects were screened and enrolled to participate 
in this study. However, 6 subjects were considered screen failures 
due to failure to meet inclusion criteria or meeting exclusion 
criteria, and 20 subjects were removed from the study due to 
protocol deviations that could affect our data analysis. Deviations 
from the protocol included anesthesia care staff not administrat-
ing the triple therapy as directed, prolonged intubation after 
surgery, and/or loss of follow-up. Ninety-five subjects completed 
the study: 48 in the aprepitant group and 47 in the ondansetron 
group (Figure 1). No adverse events related to study medications 
were documented.
There were no statistically significant differences among 
subjects’ demographics, risk factors for PONV, duration of anes-
thesia, and postoperative opioid consumption between the two 
groups (Table 1).
The overall incidence of PONV during the first 24  h after 
surgery was 31.0% (n = 15) in the aprepitant group and 36.2% 
(n = 17) for the ondansetron group.
The median severity of postoperative nausea between the 
aprepitant group and the ondansetron group was 6 and 5, 
respectively (Table  2). The overall incidence of vomiting dur-
ing the first 24 h in the aprepitant group was 8% (n = 4), with a 
median worst vomiting score of 2.5. Similarly, the occurrence and 
severity of postoperative vomiting in the ondansetron group was 
12.8% (n = 6), with a median worst vomiting score of 3. Rescue 
antiemetics during the first 24 h after surgery were required for 
29% (n = 14) of the aprepitant group and for 36.2% (n = 17) of 
the ondansetron group. There were no statistically significant 
differences between PONV outcome variables between the two 
groups (Table 2).
From the period of 0 to 120 h following surgery, the sever-
ity of vomiting was significantly lower in the aprepitant group 
compared with the ondansetron group (2 versus 6%, P = 0.008). 
However, there was no difference between the two groups from 0 
to 2, 0 to 24, or 24 to 120 h (Table 3).
There were no statistically significant differences between 
the two groups in the number of vomiting episodes, incidence 
or severity of nausea, need for rescue antiemetic’s, or complete 
response from 0 to 2, 0 to 24, 0 to 120, or 24 to 120 h (Tables 2 
and 3).
The median time to first emetic and significant nausea epi-
sodes was 7.6 (2.9, 48.7) and 14.3 (4.4, 30.7) hours, respectively, 
for the aprepitant group and 6.0 (2.2, 29.5) and 9.6 (0.7, 35.2) 
hours, respectively, for the ondansetron group. The median time 
for the first rescue medication was 15.3 (5.3, 31.2) hours for the 
aprepitant group and 9.6 (0.7, 35.2) hours for the ondansetron 
group. There were no statistically significant differences in these 
times (Table 4).
DiSCUSSiOn
This pilot study presents similar results between the triple therapy 
of aprepitant, promethazine, and dexamethasone versus the triple 
therapy of ondansetron, promethazine, and dexamethasone in 
preventing nausea and vomiting after craniotomies under gen-
eral anesthesia. Therefore, both treatments could be considered 
adequate alternatives for PONV treatment when compared with 
other treatment regimens in subjects undergoing craniotomy. On 
the one hand, the results demonstrate no statistical significance 
between both groups. On the other hand, when compared with 
the overall incidence of PONV in general population (30–80%) 
TaBlE 1 | Patient demographics and surgical variables.
Demographics and surgical variables aprepitant 
group
Ondansetron 
group
Number of subjects 48 47
Age, mean (SD), years 52.1 ± 14.5 51.4 ± 16.8
Weight, mean (SD), kg 86.2 ± 21.6 86.8 ± 18.6
Height, mean (SD), cm 170.7 ± 10.3 169.3 ± 10.5
BMI, mean (SD) 29.5 ± 6.5 30.5 ± 7.3
Race-White, n (%) 46 (96) 43 (91)
ASA I/II/III 13/34/1 13/28/6
Female, n (%) 26 (54) 25 (53)
History of PONV and/or motion of sickness n (%) 19 (40) 17 (36)
Non-smoker status, n (%) 35 (73) 36 (77)
Postoperative opioids, n (%) 48 (100) 47 (100)
Apfel risk factors, n (%)
1 (Low risk) 12 (25) 11 (23)
2 (Moderate risk) 19 (40) 21 (45)
3 or 4 (High risk) 17 (35.4) 15 (32)
Duration of anesthesia, mean (SD), h 5.14 ± 2.20 5.75 ± 3.15
Duration of SICU stay, mean (SD), h 35.6 ± 27.3 45.0 ± 37.7
Duration of total hospital stay, mean (SD), h 53.3 ± 62.0 55.0 ± 48.6
n, total number; %, percentage.
TaBlE 2 | Postoperative nausea and vomiting outcome variables in the 
first 24 h.
aprepitant  
group
Ondansetron 
group
P-value
Number of subjects 48 47 NA
PONV, n (%) 15 (31) 17 (36.2) 0.611
Vomiting, n (%) 4 (8) 6 (12.8) 0.481
Worst vomiting score, 
median (IQR)
1.5 (1, 2.5) 3 (3, 3) 0.100
Any nausea incidence, n (%) 15 (31) 17 (36.2) 0.611
Significant nausea incidence 
(A score ≥4 on the VRS), 
n (%)
11 (23) 14 (29.8) 0.445
Worst nausea score,  
median (IQR)
6 (3, 7) 5 (4, 7) 0.705
Rescue antiemetics, n (%) 21 (44) 25 (53) 0.357
Postoperative opioid 
consumption (oral morphine 
mg), median (IQR)
54.0 (37.5, 105.0) 75.0 (30.0, 122.5) 0.830
IQR, interquartile range; %, percentage; n, total number; NA, not applicable; VRS, 
verbal rating scale.
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and patients undergoing craniotomy (43–70%), both treatments 
lowered the incidence of PONV in all subjects, and even more 
significantly in subjects with three or four of Apfel’s risk factors 
(1, 6–8, 12).
Postoperative nausea and vomiting is classed as early PONV 
(on-setting between 0 and 2 h after surgery) or delayed PONV 
(on-setting between 2 and 24 h after surgery) (1, 7). Additionally, 
episodes of nausea and vomiting that occur after the patient 
leaves an institution is classified as post-discharge nausea and 
vomiting (PDNV) (1, 7). Several studies have reported a general 
postoperative incidence of 30% for nausea and 50% for vomiting, 
and as high as 80% incidence in patients classified as high risk by 
the Apfel Simplified Risk Score (1, 6–8, 12).
Current guidelines from SAMBA that include data from 
several meta-analyses confirm that the known risk factors for 
PONV do indeed factor into a patient’s development of PONV 
(1). As a result, the Apfel Score continues to be the preferred pre-
operative tool for PONV assessment (1, 19). The simplified Apfel 
score for the prediction of PONV is based on the following four 
criteria: female gender, history of PONV or a past medical history 
of motion sickness, non-smoking status, and expected postop-
erative opioid use. Each risk factor will increase the incidence of 
PONV in patients by ~20%, female gender being the strongest 
predictor (1, 19). The Apfel score considers low, medium, and 
high risk of developing PONV to be patients with 0–1, 2 or 3, and 
more than 3 risk factors, respectively (19). Consequently, it has 
been reported that patients presenting two or more risk factors 
are more likely to benefit from treatment prophylaxis. Also, the 
current SAMBA guidelines showed that PONV incidences were 
higher in cholecystectomy and gynecology surgeries (1, 20); nev-
ertheless, previous studies demonstrated that patients who have 
undergone craniotomies had an average incidence of PONV as 
high as 50–70%. However, most of these studies did not clearly 
document standardized treatment regimens (1, 4, 7, 10, 11).
The use of a combination of two or more drugs to prevent 
PONV is known as multimodal therapy, and its use is recom-
mended in patients with high risk for PONV (1). The multimodal 
approach recommended by current SAMBA guidelines in adults 
includes double therapy with 5-HT3 receptor antagonist + dexa-
methasone or droperidol, dexamethasone  +  droperidol or 
ondansetron + casopitan or triple therapy with 5-HT3 receptor 
antagonist + dexamethasone + droperidol (1). Conversely, there 
are not sufficient studies reporting the experience of using mul-
timodal approach with double or triple therapy, particularly in 
the craniotomy patient population (Table 5). Therefore, the need 
for multimodal therapy trials with different regimens to prevent 
PONV was necessary.
A randomized trial conducted by Habib et al. compared the 
use of aprepitant and dexamethasone versus ondansetron and 
dexamethasone to prevent PONV in patients undergoing crani-
otomy (10). Based on data analysis, 104 subjects completed the 
study. Of these, 53 subjects were allocated to the ondansetron 
group and 51 to the aprepitant group. The study concluded that 
the incidence of vomiting during the early postoperative period 
(0–2 h) was significantly lower in the aprepitant group versus 
the ondansetron group (6 versus 21%) (10). In addition, the 
authors reported 36% incidence of vomiting for the ondansetron 
group and 14% for the aprepitant group. However, there was 
no statistical difference in the incidence and severity of nausea 
between both groups during the early and/or 24 h postoperative 
period (10).
The literature suggests that the impact of NK1 antagonists, 
such as aprepitant, on the central nervous system may possess 
a better efficacy than 5HT3 receptor antagonists, which have a 
mechanism of action predominately on the peripheral level (2, 9, 
10, 16, 17). NK1 antagonists have also demonstrated their efficacy 
in the prevention of chemotherapy-induced nausea and vomiting 
in patients receiving moderately emetogenic chemotherapy (17). 
Hence, it has also been proposed to be an effective PONV pro-
phylactic medication in neurosurgical procedures. Aprepitant 
TaBlE 4 | intent to treat population.
Time to treatment failure, 
median (iQr), h
aprepitant group, 
N = 48
Ondansetron 
group, N = 49
P-value
Time to first emetic episode 7.6 (2.94, 48.7) 6.0 (2.2, 29.5) 0.483
Time to first rescue 15.3 (5.3, 31.2) 9.6 (0.7, 35.2) 0.444
Time to first significant 
nausea
14.3 (4.4, 30.7) 9.6 (0.7, 35.2) 0.444
IQR, interquartile range; N, total number.
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has been documented to be effective up to 48 h postoperatively, 
with minimal sedative effects (2, 16).
Gan et al. published a pilot study exploring the role of aprepitant 
in preventing PONV. In this double-blinded study, 805 patients 
undergoing open-abdominal surgery were randomly assigned a 
treatment of 40 mg aprepitant orally, 125 mg aprepitant orally, or 
4 mg ondansetron IV in order to evaluate PONV and necessity for 
rescue therapy up to 48 h postoperatively (2). Aprepitant proved 
to be superior to ondansetron for the prevention of postoperative 
vomiting (90% with 40 mg aprepitant, 95% with 125 mg aprepi-
tant, and 74% with ondansetron) (2). No significant differences 
in PONV were found between the two doses of aprepitant (2). 
Also, no significant differences were noted between aprepitant 
and ondansetron for nausea control or the need for rescue (2).
Long et  al. performed a prospective, randomized, placebo 
controlled outcomes trial of aprepitant with patients undergoing 
elective hysterectomy (21). This study catered toward a popula-
tion where Apfel’s risk factors were considered (21). A total of 
256 women received either oral aprepitant 40 mg or placebo in 
addition to an established prophylactic regimen of dexametha-
sone and ondansetron (21). There was a trend showing that the 
addition of aprepitant to the regimen lowered the incidence of 
both nausea (24 versus 38%) and vomiting (17 versus 29%) over 
the first 24 h after surgery compared with the placebo (21). The 
need for additional antiemetic medication was also lower in the 
aprepitant group than in the placebo group (42 versus 60%) (21).
In 2007, Diemunsch et al. explored aprepitant’s NK1 antagonist 
properties as a preventative measure for PONV in patients under-
going open-abdominal surgery (22). They compared the efficacy 
of IV ondansetron 4 mg to experimental doses of oral aprepitant 
40 mg and oral aprepitant 125 mg. Both experimental doses of 
aprepitant were shown to be no less effective in achieving the 
study’s primary endpoint – that is, no vomiting or use of rescue 
therapy 0–24 h after surgery (CI > 0.65) (22). Additionally, it was 
shown that aprepitant was greatly more effective in preventing 
vomiting and reducing nausea from 24–48 h after surgery (22).
Ham et al. performed a similarly designed prospective study 
that investigated the effects of combining aprepitant and ondanse-
tron in patients at high risk for PONV up to 48 h postoperatively 
in female patients undergoing laparoscopic gynecologic surgery 
(23). Patients were randomly assigned to receive IV ondansetron 
4 mg and oral aprepitant 80 mg or IV ondansetron 4 mg and a pla-
cebo (23). When examining a smaller time interval, 0–1 h, there 
was no significant difference between the incidences of PONV 
(23). However, the aprepitant–ondansetron therapy proved to be 
more effective in reducing PONV incidence 1–48 h after surgery 
compared with ondansetron alone (8 versus 19%) (23).
TaBlE 5 | Characteristics of studies included in the discussion.
no. reference Surgery type intervention no. of 
groups
Measured outcome and time Study design results
1 Gan  
et al. (2)
Open-abdominal 
surgery under 
general anesthesia
PO aprepitant 40 mg  
or  
PO aprepitant 120 mg  
or  
IV ondansetron 4 mg
3 Incidence of vomiting Multicenter double-
blind randomized trial
Complete response was not different between groups
Aprepitant groups experienced lower incidence of 
postoperative vomiting than ondansetron group
No significant difference in nausea score and use of 
rescue between groups
No significant differences between the aprepitant groups
Need for rescue
Nausea score
Complete response
Cumulative incidence for day 1
2 Tsutsumi 
and  
Kakuta (9)
Elective craniotomy 
under general 
anesthesia
IV fosaprepitant 150 mg  
or  
IV ondansetron 4 mg
2 Incidence of PONV Prospective  
double-blind 
randomized trial
Fosaprepitant group experienced lower incidence of 
vomiting than ondansetron groupNeed for rescue
Pain score Incidence of complete response higher in fosaprepitant 
group than ondansetron groupCumulative incidence until day 2 
with individual values for day 1
3 Habib  
et al. (10)
Craniotomy under 
general anesthesia
PO aprepitant 40 mg  
or  
IV ondansetron 4 mg
2 Incidence of vomiting Prospective  
double-blind 
randomized trial
Aprepitant group experienced lower incidence of 
postoperative vomiting
Nausea score and need for rescue were not different 
between groups
Need for rescue
Nausea score
Cumulative incidence until day 2 
with individual values for day 1
4 Rapoport 
et al. (17)
Moderately 
emetogenic 
chemotherapy
PO aprepitant 125 mg, PO ondansetron 
8 mg, PO dexamethasone 12 mg prior to 
chemo, and PO aprepitant 80 mg for 2 days 
post-chemo  
or  
PO ondansetron 8 mg, PO dexamethasone 
20 mg prior to chemo and PO ondansetron 
8 mg for 2 days post-chemo every 12 h
2 Incidence of vomiting Prospective  
double-blind 
randomized  
parallel-group trial
Aprepitant group experienced significantly lower incidence 
of vomiting for 2 days post-chemoComplete response
Cumulative incidence until day 5
5 Long  
et al. (21)
Elective 
hysterectomy
PO aprepitant 40 mg  
or  
placebo
2 Incidence of vomiting Prospective  
double-blind 
randomized trial
Trend suggesting reduction in vomiting, nausea score, 
and need for rescue in aprepitant group compared with 
placebo group
Need for rescue
Nausea score
Cumulative incidence for day 1
6 Diemunsch 
et al. (22)
Open-abdominal 
surgery under 
general anesthesia
PO aprepitant 40 mg  
or  
PO aprepitant 125 mg  
or  
IV ondansetron 4 mg
3 Incidence of vomiting
Need for rescue
Nausea score
Complete response
Cumulative incidence until day 2 
with individual values for day 1
Double-blind 
randomized  
phase III trial
Aprepitant groups non-inferior to ondansetron group for 
complete response
Aprepitant groups superior to ondansetron group in 
preventing vomiting up to 48 h postoperatively
Distribution of peak nausea scores lower in aprepitant 
groups compared with ondansetron group
Similar efficacy between the two aprepitant groups, 
suggesting a possible plateau in response
7 Ham  
et al. (23)
Laparoscopic 
gynecologic 
surgery
IV 4 mg Ondansetron in combination with 
PO aprepitant 80 mg  
or  
placebo
2 Incidence of PONV
Need for rescue
Impact of PONV on daily life 
by FLIE
Cumulative incidence until day 2
Prospective  
double-blind 
randomized trial
Incidence of PONV within an hour postoperatively was 
lower in aprepitant group than in placebo group
No difference in use of rescue between groups
No difference in impact of PONV on daily life between 
groups
(Continued)
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Tsutsumi et al. designed a similar randomized study that evalu-
ated the effects of IV fosaprepitant versus IV ondansetron on the 
prevention of PONV in neurosurgery patients (24). Fosaprepitant 
is a chemically modified form of aprepitant that increases its 
solubility and that, once delivered into the body, is converted to 
aprepitant (24). When examining smaller time intervals, 0–2 h, 
there were no significant differences between the incidences of 
PONV (24). However, the fosaprepitant group demonstrated a 
higher complete response ratio as well as a lower incidence of 
vomiting when compared with ondansetron at the 24- and 48-h 
time point (24). Their results further suggest that the use of 
NK1 antagonists may be advantageous in diminishing episodes 
of vomiting if given pre-operatively in this type of surgery (24). 
Additionally, the use of IV fosaprepitant could substitute oral 
aprepitant because it satisfies anesthetists’ concerns about no oral 
consumption before surgery while still displaying the effective 
antiemetic effects of aprepitant.
Shilpa et al. published a double-blind, randomized controlled 
trial comparing the efficacy of clonidine versus ondansetron 
(25). This prospective study randomly assigned 60 patients with 
an ASA score of I or II into an ondansetron group or a clonidine 
group (25). Those in the ondansetron group received 8  mg of 
oral ondansetron, while the clonidine group received 150  μg 
of clonidine as premedication. Both groups received 8  mg of 
dexamethasone intravenously. A larger percentage of patients in 
the clonidine group developed PONV than in the ondansetron 
group (36.7 versus 30%) (25). For the patients who experienced 
nausea and vomiting, those in the clonidine group experienced it 
during the 1–2 h postoperative period and those in the ondanse-
tron during the 6–12 h postoperative period (25). Therefore, the 
study concluded that ondansetron with dexamethasone is more 
effective in controlling PONV when compared with clonidine 
with dexamethasone (25). Nonetheless, in our study, 36.2% of the 
patients in the ondansetron group experienced PONV.
In 2012, Alonso-Damián and Anguiano-García compared the 
efficacy of aprepitant 80 mg and ondansetron 4 mg in prevent-
ing PONV in a total of 60 patients undergoing open-abdominal 
surgery (26). The study’s results showed that subjects who had 
been given aprepitant had less nausea than the subjects who had 
been dosed with ondansetron on arrival to the post-anesthesia 
recovery room (3.3 versus 53.3%; P < 0.001) and 6 h postopera-
tively (0 versus 33.3%; P = 0.002) (26).
A meta-analysis of three studies (Gan et al., Diemunsch et al., 
and Habib et al.) with 1171 total subjects, performed by Liu et al., 
compared the efficacy of aprepitant 40  mg and ondansetron 
4  mg in preventing PONV. The meta-analysis demonstrated 
that the dose of aprepitant was more effective than the dose of 
ondansetron in preventing vomiting (P < 0.001) (27). The overall 
incidence of PONV for subjects dosed with aprepitant was 13.3% 
(95% CI = 9.5–18.4) and 28.4% (95% CI = 24.6–32.9) for subjects 
dosed with ondansetron (27).
A recently published, evidence-based review by Milnes et al. 
evaluated the efficacy of aprepitant in decreasing the incidence of 
PONV (28). After a thorough search using CINAHL, MEDLINE, 
EMBASE, and Google Scholar for publications dating from 2007 
to 2014, 23 articles were found, 10 of which were relevant to our 
study (28). Eight randomized controlled trials, one prognostic 
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study, and one post hoc analysis were reviewed (2, 10, 22, 28–34). 
Although the end points of the studies varied, all of the studies 
concluded that aprepitant decreased the incidence of PONV as 
compared with ondansetron (28).
In regard to its approved role as an add-on to standard 
antiemetic treatment, aprepitant holds promising evidence of 
clinical effectiveness. Nevertheless, aprepitant’s high price raises 
the question of its cost-effectiveness (35). Utilizing aprepitant in 
100 patients costs $31,000 (25,000€), while aprepitant’s average 
clinical benefit is the avoidance of 15 cases of PONV for every 
100 patients (35).
Our study had some limitations that should be recognized. 
The first limitation is the anesthesia care provider’s concern of 
the pre-operative oral administration of aprepitant/placebo. As 
a result, standard anesthesiologists’ suggestion of 12  h of pre-
operative fasting was not met. A future trial should experiment 
with fosaprepitant, which is delivered into the body intravenously 
and then converted to aprepitant (24). Another limitation that 
should be addressed is that postoperative opioids were admin-
istered to all patients as needed, despite introducing them to an 
additional Apfel risk factor for PONV. As a result, patients who 
reported experiencing more pain required higher doses of rescue 
opioid medications. Because patients received variable doses of 
postoperative opioids, a confounding variable was introduced 
into this study, as higher doses of opioids further increase the 
risk for PONV. Also, the type of surgery that patients in the 
study underwent may also have interfered in the results of our 
study. The postoperative symptoms of subjects undergoing 
craniotomies include, but are not limited to, headaches, diz-
ziness, and nausea. Due to the nature of this type of surgery, it 
was impossible for us to associate these symptoms specifically 
to the surgical procedure, anesthesia regimen, or adverse events 
related to study medications. Another limitation of our study 
was a discrepancy between the approved and our standard of 
care administration time of ondansetron IV. The packaging of 
ondansetron instructs anesthesia care providers to administer 
it at induction of anesthesia. Nevertheless, in a clinical setting, 
they administer the drug at the end of surgery, right before 
anesthesia emergence. On the other hand, the literature shows 
that antiemetics are more effective when administered toward the 
end of surgery rather than induction (16). For instance, it takes 
3  h for aprepitant to reach its maximum blood concentration; 
therefore, administrating it at the end of surgery could reduce 
the optimal capacity of its antiemetic properties after anesthesia 
emergence. And finally, the recommended rescue therapy for 
both groups was the administration of ondansetron 4  mg IV. 
The study design intended to apply standard of care institutional 
guidelines in order to maintain consistency of rescue medication 
administration. It might be arguable that patients randomized to 
the ondansetron arm received, as a rescue medication, the same 
drug, leading to double dosing. Future trials will benefit from a 
detailed analysis of our own pilot study limitations.
COnClUSiOn
The primary goal of this pilot study was to compare the efficacy of 
triple therapy with aprepitant, dexamethasone, and promethazine 
versus triple therapy with ondansetron, dexamethasone, and pro-
methazine for the prevention of PONV in patients undergoing 
craniotomies. Our results showed an overall incidence of PONV 
of 31.0 and 36.2% for aprepitant and ondansetron, respectively. 
In conclusion, this study showed similar adequacy of both PONV 
prophylaxis regimens in subjects undergoing neurological sur-
gery with general anesthesia. Future trials testing new PONV 
prophylaxis regimens in this surgical population should be 
performed to gain a better understanding of how to best provide 
prophylactic treatment.
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